Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India, EU FTA Talks Said Leading To Loss Of Essential Drug Access

This article was originally published in PharmAsia News

Executive Summary

India's free trade agreement being negotiated with the European Union is being criticized in some quarters as leading to much of the population losing access to essential drugs

You may also be interested in...

Indian Pharma Lobby Flays India-EU Trade Talks; Debunks "TRIPS Plus" Provisions On Patent Extensions And Data Protection

MUMBAI - Hardball negotiations between Indian and European Union representatives on the signing of a free trade agreement may lead to flare ups after the Indian Pharmaceutical Alliance - a powerful industry lobby - raised strong objections on provisions related to intellectual property rights that are sought to be incorporated in the draft treaty

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts